Evaluation of single and multiple doses of a novel mGlu2 agonist, a potential antipsychotic therapy, in healthy subjects.
Eli Lilly and Company, Windlesham, UK.
Eli Lilly and Company, Indianapolis, Indiana, USA.
Lilly-NUS Centre for Clinical Pharmacology, Singapore.
- Published Article
British Journal of Clinical Pharmacology
Wiley (Blackwell Publishing)
- Publication Date
Aug 01, 2017
Oral doses of LY2979165 up to 60 mg as a single dose and up to 400 mg given as multiple QD doses, using a titration regimen, were well tolerated with linear PK. Overall, these data support further clinical evaluation of LY2979165.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 06/09/2018 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/28156011